Competition Law and Strategic Diagnostic Platforms and Antitrust

Introduction

Strategic diagnostic platforms are digital or technology-enabled systems through which diagnostic services, laboratories, hospitals, physicians, patients, insurers, medical-device manufacturers, or healthcare marketplaces interact. They may include laboratory-booking platforms, diagnostic aggregators, pathology networks, AI-assisted diagnostic systems, genomic-testing platforms, radiology platforms, connected diagnostic-device ecosystems, and platforms controlling access to diagnostic data.

From a competition-law perspective, these platforms can generate substantial efficiencies—faster diagnosis, lower transaction costs, interoperability, wider patient access and improved utilisation of laboratories—but they can also become strategic control points. A platform may obtain market power through control over patient referrals, diagnostic data, laboratory capacity, software interfaces, accreditation, algorithms, APIs, device compatibility or distribution channels.

The principal competition concerns are therefore dominance, exclusionary conduct, tying, refusal of access, discriminatory access, self-preferencing, exclusive arrangements, data advantages, interoperability restrictions, algorithmic coordination and anticompetitive mergers.

1. Meaning of a Strategic Diagnostic Platform

A strategic diagnostic platform generally combines three elements:

1. Diagnostic infrastructure – laboratories, imaging centres, testing devices or clinical systems.
2. Digital intermediation – software, marketplaces, APIs, booking systems or referral networks.
3. Data and analytical capabilities – patient information, test results, diagnostic algorithms and historical datasets.

The strategic importance of the platform increases when competitors cannot realistically reproduce these assets.

Example

A platform may simultaneously control:

Patient referrals → diagnostic booking → laboratory allocation → test processing → diagnostic result → patient record → AI analysis.

If competitors depend upon that platform at several stages, the platform may become an important competitive bottleneck.

2. Relevant Competition-Law Framework

The precise legal framework depends upon the jurisdiction. In India, the principal provisions are found in the Competition Act, 2002, particularly:

• Section 3 – anti-competitive agreements;
• Section 4 – abuse of dominant position;
• Section 5 – combinations;
• Section 6 – regulation of combinations;
• Section 19 – inquiry into combinations and anti-competitive conduct;
• Sections 26–29 – investigation and merger review mechanisms.

For digital diagnostic platforms, Section 4 can become particularly important where the platform possesses substantial market power.

3. Defining the Relevant Market

The first question is whether the platform possesses market power.

The relevant market may be defined by:

A. Service

Possible markets include:

• diagnostic testing services;
• pathology services;
• radiology services;
• laboratory-testing marketplaces;
• online diagnostic booking;
• AI diagnostic software;
• genomic testing;
• diagnostic-data analytics.

B. Customer group

A platform may serve:

• patients;
• hospitals;
• physicians;
• laboratories;
• insurers;
• pharmaceutical companies;
• medical-device manufacturers.

Different customer groups may constitute separate but interconnected markets.

C. Geographic market

A market could be:

• local;
• regional;
• national;
• international.

Digital platforms may appear geographically broad, but physical laboratory capacity can make the underlying diagnostic service highly local.

4. Platform-Specific Market Power

Traditional market-share analysis may not fully capture the power of diagnostic platforms.

Important indicators include:

• number of patients;
• number of laboratories;
• number of hospitals connected;
• diagnostic-data volume;
• network effects;
• switching costs;
• interoperability;
• exclusivity;
• control of APIs;
• access to proprietary datasets;
• algorithmic advantages;
• device compatibility;
• reputation and trust;
• regulatory or accreditation barriers.

A platform with a moderate market share may nevertheless possess significant strategic power if competitors depend upon it for essential inputs or access to customers.

5. Network Effects

Diagnostic platforms frequently exhibit network effects.

More laboratories attract more patients.

More patients generate more diagnostic data.

More data may improve algorithms.

Improved algorithms attract more physicians.

More physicians generate additional patient referrals.

This creates a feedback loop:

Users → Data → Better diagnostics → More users → More data

The resulting network can make market entry increasingly difficult.

6. Data as a Competitive Asset

Diagnostic data can be commercially and competitively significant.

A platform may accumulate:

• historical test results;
• imaging datasets;
• genomic information;
• laboratory-performance information;
• physician referral patterns;
• patient preferences;
• diagnostic outcomes.

The competition issue arises where control over data gives the platform an advantage that rivals cannot reasonably replicate.

Possible concerns include:

• refusing reasonable data portability;
• preventing interoperability;
• exclusive control of diagnostic datasets;
• discriminatory API access;
• using downstream data to disadvantage rivals;
• combining datasets from different markets;
• acquiring a competitor principally to obtain its data.

Privacy and competition law are distinct, but they can intersect where data practices affect market structure.

7. Self-Preferencing

A diagnostic platform may operate both as:

Platform operator + diagnostic provider

For example, it could list independent laboratories while simultaneously operating its own laboratory network.

It may then:

• place its own laboratories at the top of search results;
• give preferential algorithmic visibility to affiliated laboratories;
• provide better referral information to its own services;
• impose additional requirements on independent laboratories.

The competition-law question is whether such conduct excludes equally efficient competitors.

8. Refusal of Access

A platform may control an important:

• diagnostic API;
• booking interface;
• patient-referral channel;
• device interface;
• diagnostic database;
• interoperability layer.

If competitors cannot effectively compete without access, refusal may raise concerns under abuse-of-dominance principles.

However, not every refusal is unlawful.

Authorities generally need to consider:

• whether the platform is dominant;
• whether the input is genuinely indispensable;
• whether duplication is feasible;
• whether refusal has exclusionary effects;
• whether there is an objective justification;
• whether access can be provided without disproportionate technical or security risks.

9. Interoperability Restrictions

Interoperability is particularly important in healthcare technology.

A dominant diagnostic platform might prevent competitors from connecting to:

• electronic health records;
• laboratory information systems;
• imaging systems;
• hospital software;
• medical devices;
• patient portals.

This can create technical foreclosure.

The platform effectively becomes a technological gatekeeper.

10. Tying and Bundling

A diagnostic platform could require customers to purchase:

Diagnostic software + laboratory services

or

Diagnostic device + proprietary analytics platform

or

Booking platform + payment service.

Tying becomes particularly significant when:

1. the tying product has market power;
2. the tied product is distinct;
3. customers are effectively forced to obtain both;
4. the arrangement has potential foreclosure effects.

11. Exclusive Dealing

Platforms may require laboratories or hospitals to deal exclusively with them.

For example:

"A laboratory using our diagnostic marketplace cannot simultaneously participate in competing platforms."

Such arrangements may produce legitimate benefits, such as investment protection or quality assurance, but may also prevent rival platforms from achieving sufficient scale.

Relevant factors include:

• duration;
• market coverage;
• number of laboratories bound;
• availability of alternatives;
• platform market share;
• switching costs.

12. Algorithmic Discrimination

Diagnostic platforms may use algorithms to rank:

• laboratories;
• tests;
• physicians;
• hospitals;
• diagnostic packages.

Competition problems may arise if the platform secretly manipulates ranking to favour its own affiliated services.

The issue becomes particularly difficult where ranking criteria are opaque.

A competition authority may examine:

• ranking methodology;
• changes in algorithmic treatment;
• internal communications;
• differential access to data;
• effects on rival laboratories.

13. Algorithmic Coordination

Diagnostic platforms can also facilitate coordination between competitors.

For example, competing laboratories using the same pricing algorithm could potentially converge on similar prices.

The important distinction is between:

• independent algorithmic pricing, and
• algorithm-mediated coordination involving communication, common parameters or conscious alignment.

Competition authorities increasingly examine whether technology merely facilitates competition or instead makes coordination easier.

14. Diagnostic Platforms and Merger Control

Mergers involving diagnostic platforms require particular attention because an acquisition may remove a future competitor before it becomes significant.

Potential concerns include:

Platform + laboratory

A digital platform acquires a major laboratory network.

Platform + diagnostic software

A marketplace acquires a competing diagnostic technology.

Platform + data company

A diagnostic platform acquires a company possessing valuable datasets.

Platform + AI company

A large healthcare platform acquires a promising AI-diagnostic entrant.

Authorities may therefore examine:

• horizontal overlaps;
• vertical foreclosure;
• conglomerate effects;
• data concentration;
• innovation competition;
• potential competition;
• access to APIs;
• interoperability.

15. Relevant Case Laws

The following cases provide important principles applicable to strategic diagnostic platforms, even where the underlying industry was not diagnostics.

1. United States v. Microsoft Corp. (2001)

The U.S. courts examined Microsoft's conduct involving the Windows operating system and competing web browsers.

Principle

Control over an important technological platform can be used to disadvantage competing products.

Relevance to diagnostic platforms

A dominant diagnostic operating layer could potentially use:

• technical restrictions;
• default settings;
• APIs;
• compatibility requirements;

to disadvantage competing diagnostic applications.

The case demonstrates the importance of distinguishing legitimate product integration from exclusionary platform conduct.

2. Google Search (Shopping) – European Commission, 2017

The European Commission found that Google had favoured its own comparison-shopping service in search results over competing comparison services.

Principle

A dominant platform's control over an important access point can create competition concerns where it systematically favours its own downstream service.

Diagnostic-platform relevance

A dominant diagnostic marketplace could potentially favour:

• its own laboratories;
• affiliated imaging centres;
• proprietary diagnostic tests;
• its own AI tools.

The core issue would be whether the platform is using control over intermediation to disadvantage competitors.

3. Google Android – European Commission, 2018

The European Commission examined Google's practices involving Android, including tying and contractual restrictions affecting competing search and browser services.

Principle

Bundling and contractual restrictions imposed by a powerful platform can reinforce dominance in interconnected markets.

Diagnostic relevance

A dominant diagnostic-device ecosystem could potentially require users to adopt:

device + proprietary diagnostic software + proprietary analytical service.

The Android case illustrates why competition authorities examine the interaction between technological ecosystems and adjacent markets.

4. Bronner v Mediaprint (CJEU, 1998)

This case concerned access to a newspaper home-delivery system.

The Court established stringent conditions for treating access to infrastructure as legally required under the essential-facilities doctrine.

Principle

A refusal to provide access is not automatically abusive merely because the infrastructure is important.

Among the relevant considerations are:

• indispensability;
• absence of realistic alternatives;
• inability to duplicate;
• potential elimination of competition.

Diagnostic relevance

A diagnostic platform controlling a genuinely indispensable interoperability system could potentially raise similar issues.

5. IMS Health v NDC Health (CJEU, 2004)

This case is particularly relevant to healthcare and information infrastructure.

It concerned access to a pharmaceutical-sales information system based on data structures used for market analysis.

Principle

The case developed the circumstances in which refusal to license or provide access to an intellectual-property-protected system could constitute abuse.

The Court emphasised exceptional circumstances involving factors such as indispensability and elimination of competition.

Diagnostic-platform relevance

A dominant diagnostic-data platform could argue that its database or architecture is proprietary.

Competitors, however, may contend that access is necessary to compete effectively.

The case therefore provides an important framework for analysing:

• diagnostic databases;
• proprietary data structures;
• interoperability;
• licensing;
• access to information systems.

6. Slovak Telekom v Commission (CJEU, 2021)

The case concerned access to telecommunications infrastructure and alleged margin-squeeze conduct.

Principle

A vertically integrated dominant undertaking can face competition-law scrutiny where its conduct prevents downstream competitors from competing effectively.

Diagnostic relevance

Consider a dominant diagnostic infrastructure provider that supplies:

Diagnostic infrastructure → software platform → downstream diagnostic services.

If it supplies competitors on terms that prevent economically viable downstream competition while competing downstream itself, margin-squeeze principles may become relevant.

7. MEO v Autoridade da Concorrência (CJEU, 2017)

This case concerned allegedly discriminatory pricing by a dominant undertaking.

Principle

Different prices or conditions offered to trading partners do not automatically constitute abusive discrimination. The competitive effects of the differential treatment must be examined.

Diagnostic relevance

A diagnostic platform could charge different:

• commission rates;
• API fees;
• access charges;
• ranking fees;

to different laboratories.

The legal analysis would require examination of whether the discrimination produces competitive harm rather than simply identifying price differences.

8. Intel v Commission (CJEU, 2017)

The case involved rebates offered by Intel and the assessment of exclusionary effects.

Principle

In appropriate circumstances, competition authorities must examine whether rebates are capable of producing exclusionary effects rather than treating every loyalty-inducing rebate as automatically abusive.

Diagnostic relevance

A dominant diagnostic platform might offer laboratories:

lower commissions for exclusive participation.

The competitive analysis would examine coverage, duration, exclusivity, rivals' ability to compete and actual or potential foreclosure.

9. Qualcomm (CJEU, 2022)

The Qualcomm litigation concerned payments associated with exclusivity and the assessment of exclusionary conduct in the semiconductor sector.

Principle

Exclusive or loyalty-inducing financial arrangements by a powerful technology supplier can be scrutinised for their ability to foreclose competitors.

Diagnostic relevance

Similar issues can arise if a diagnostic platform gives hospitals or laboratories financial incentives to remain exclusive.

16. Six Core Competition Theories for Diagnostic Platforms

The principal theories can be organised as follows:

17. Strategic Diagnostic Data Concentration

Data concentration deserves separate treatment.

Suppose Platform A possesses:

100 million diagnostic records + imaging data + outcomes + physician referral data.

A new competitor may technically be able to build a diagnostic algorithm but lack the dataset required to achieve comparable performance.

This can create a data-driven entry barrier.

Competition analysis should therefore distinguish between:

Data that is replicable

Competitors can independently collect comparable information.

Data that is difficult to replicate

The platform possesses a unique historical dataset.

Data that is indispensable

Competitors cannot reasonably compete without access.

Only the latter category presents the strongest potential competition concerns, and even then the legal test remains conduct- and jurisdiction-specific.

18. Privacy and Competition Law

Diagnostic platforms operate within heavily regulated healthcare environments.

Consequently, competition remedies cannot simply disregard:

• patient confidentiality;
• medical secrecy;
• cybersecurity;
• consent requirements;
• data-protection laws;
• medical-device regulations.

A competition authority considering data access may need to design a remedy that permits competition without unnecessarily exposing sensitive patient information.

Possible solutions include:

• anonymisation;
• pseudonymisation;
• secure data rooms;
• API access;
• aggregated datasets;
• portability mechanisms;
• interoperability standards.

19. Essential-Facility Analysis

A diagnostic platform may potentially become an essential facility where competitors require access to:

• unique diagnostic infrastructure;
• an indispensable database;
• a critical interoperability interface;
• a dominant referral network.

A simplified analytical sequence is:

Is the platform dominant?

↓

Is the relevant input indispensable?

↓

Are viable alternatives available?

↓

Can the input reasonably be duplicated?

↓

Does refusal eliminate or substantially restrict competition?

↓

Is there an objective justification?

↓

Can access be provided on reasonable conditions?

This approach is consistent with the restrictive treatment of refusal-to-deal cases in European competition law.

20. Merger Remedies

Where a diagnostic-platform merger raises competitive concerns, possible remedies may include:

Structural remedies

• divestiture of laboratories;
• sale of competing diagnostic businesses;
• divestiture of specific technology assets.

Behavioural remedies

• non-discriminatory API access;
• interoperability obligations;
• data portability;
• prohibition on discriminatory ranking;
• firewalls between platform and laboratory businesses.

Governance remedies

• independent compliance monitoring;
• transparent ranking procedures;
• restrictions on use of competitively sensitive information.

21. Competition and Innovation

Diagnostic-platform competition is not limited to price.

Authorities should consider:

• diagnostic accuracy;
• speed;
• innovation;
• interoperability;
• quality;
• privacy;
• reliability;
• algorithmic improvement;
• new diagnostic modalities.

A platform could theoretically provide low prices while simultaneously reducing innovation by preventing rival diagnostic technologies from reaching patients.

Thus, innovation foreclosure can be as important as price foreclosure.

22. Special Problem of AI Diagnostic Platforms

AI introduces additional competition questions.

A dominant AI-diagnostic platform may control:

Data → Model → Cloud infrastructure → Diagnostic application → Patient interface.

This creates several possible leverage points.

A. Data advantage

Competitors cannot obtain comparable training datasets.

B. Compute advantage

The platform controls scarce computational infrastructure.

C. Distribution advantage

Hospitals are contractually or technically tied to the platform.

D. Feedback-loop advantage

More users produce more data, which improves the AI system.

E. Interoperability advantage

The platform controls interfaces connecting AI tools to clinical systems.

These factors can create cumulative barriers to entry.

23. Strategic Dependency

A particularly important concept is strategic dependency.

A diagnostic platform becomes strategically important when other businesses cannot reasonably operate without it.

For example:

Laboratory → Platform → Hospital → Patient

If the laboratory cannot reach patients without the platform, the platform possesses substantial bargaining power.

If thousands of laboratories depend upon the same platform, contractual restrictions can have market-wide consequences.

24. Competition Compliance for Diagnostic Platforms

A compliance programme should include:

Market-power assessment

Regularly assess market share, network effects and dependence.

Contract review

Review exclusivity, MFN clauses, tying and loyalty discounts.

Algorithm governance

Audit ranking and recommendation algorithms.

API governance

Ensure technically justified and non-discriminatory access policies.

Data governance

Separate legitimate privacy protections from unnecessary competitive restrictions.

Merger controls

Identify acquisitions of emerging diagnostic competitors early.

Information safeguards

Prevent competitively sensitive information obtained from laboratories from being misused against those laboratories.

25. Key Legal Questions

When analysing a strategic diagnostic platform, the following questions should be asked:

1. What is the relevant product market?
2. What is the relevant geographic market?
3. Does the platform possess dominance or substantial market power?
4. Does it control an important bottleneck?
5. Are network effects present?
6. Does it possess unique diagnostic data?
7. Can competitors switch platforms?
8. Can laboratories multi-home?
9. Is interoperability available?
10. Does the platform favour its own services?
11. Are competitors subjected to discriminatory access conditions?
12. Are exclusive contracts used?
13. Are products tied or bundled?
14. Does algorithmic ranking disadvantage competitors?
15. Does the platform engage in exclusionary pricing?
16. Are acquisitions removing potential competitors?
17. Are there objective technological or regulatory justifications?
18. What remedy would preserve competition without compromising patient safety or privacy?

Conclusion

Strategic diagnostic platforms represent a significant intersection between competition law, healthcare, data economics and digital-platform regulation.

Their competitive significance arises not merely from their market share but from control over patients, laboratories, diagnostic data, algorithms, APIs, devices, referral networks and interoperability infrastructure.

The major antitrust risks include:

Platform dominance → data concentration → interoperability control → self-preferencing → exclusivity → foreclosure → reduced innovation.

The cases of Microsoft, Google Shopping, Google Android, Bronner, IMS Health, Slovak Telekom, MEO, Intel and Qualcomm provide useful analytical principles for assessing these problems.

The central competition-law challenge is to distinguish legitimate technological integration and healthcare efficiencies from conduct that uses control over a strategic diagnostic platform to exclude competitors, raise barriers to entry, restrict interoperability or extend market power into adjacent diagnostic markets.